[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
July 1996

Adenocarcinoma in the Distal Esophagus With and Without Barrett EsophagusDifferences in Symptoms and Survival Rates

Author Affiliations

From the Departments of Surgery (Drs Johansson, Johnsson, Walther, Staël von Holstein, and Zilling) and Pathology (Dr Willén), Lund University, Lund, Sweden.

Arch Surg. 1996;131(7):708-713. doi:10.1001/archsurg.1996.01430190030008
Abstract

Objective:  To evaluate differences in clinical appearance and survival rates in patients operated on for adenocarcinoma in the distal esophagus with and without Barrett epithelium.

Design:  Prospective clinical study.

Setting:  University hospital, Sweden.

Patients:  Fifty-four patients with adenocarcinoma in the distal esophagus with (n= 17) or without (n=37) Barrett epithelium.

Intervention:  Esophagectomy or total gastrectomy. Main Outcome Measures: Preoperative symptoms, endoscopic results, and histological findings; postoperative morbidity, mortality, and survival rates.

Results:  The main indication for the endoscopic examination that revealed tumor in the group with Barrett esophagus was reflux-related symptoms in 6 patients (routine Barrett examination, n=4; symptoms of reflux, n=2), symptoms related to upper gastrointestinal tract bleeding in 6, and malignant symptoms in 5 (dysphagia, n=4; weight loss, n= 1). In contrast, most patients in the cardia cancer group were admitted because of malignant symptoms (dysphagia, n=26; epigastric pain, n=9; and anemia, n=2). Ten of 17 patients in the Barrett esophagus cancer group had tumors limited to the mucosa and submucosa only. In 1 patient the tumor grew into the muscular layer but not through it. In the remaining 6 patients the tumor did grow through the muscular layer and lymph node metastases were found. Wall penetration was found in 30 patients and metastases to lymph nodes in 29 patients in the cardia cancer group. The hospital mortality rate was 0 of 17 patients in the Barrett cancer group and 2 of 37 patients in the cardia cancer group. In the patients operated on for adenocarcinoma in the distal esophagus, a better long-term survival rate was seen in those with Barrett epithelium (50%) than in those without this metaplasia (10%) (log rank P=.005; ×2=7.80).

Conclusions:  Concomitant Barrett epithelium improved the prognosis for patients with adenocarcinoma in the distal esophagus. Probably the reason for this was a higher rate of early-stage disease, because symptoms of gastroesophageal reflux and other benign disorders, not dysphagia, were most common in patients with adenocarcinoma without Barret epithelium in the distal esophagus.Arch Surg. 1996;131:708-713

References
1.
Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ.  Barrett's oesophagus: working party report to the World Congress of Gastroenterology, Sydney, Australia, 1990 . J Gastroenterol Hepatol . 1991;6:1-22.Article
2.
Hameeteman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG.  Barrett's esophagus: development of dysplasia and adenocarcinoma . Gastroenterology . 1989;96: 1249-1256.
3.
Tytgat GNJ, Hameeteman W.  The neoplastic potential of columnar-lined (Barrett's) esophagus . World J Surg . 1992;16:308-312.Article
4.
Skinner DB, Walther BC, Riddell RH, Schmidt H, lascone C, Demeester TR.  Barrett's esophagus: comparison of benign and malignant cases . Ann Surg . 1983;198:554-566.Article
5.
Spechler JS, Robbins AH, Rubins H, et al.  Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology . 1984;87:927-933.
6.
Menke-Pluymers MBE, Schoute NW, Mulder AH, Hop WCJ, Van Blankenstein M, Tilanus HW.  Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus . Gut . 1992;33:1454-1458.Article
7.
Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau EL.  Esophageal acid sensitivity in Barrett's esophagus . J Clin Gastroenterol . 1987;9:23-27.Article
8.
Akiyama H, Tsurumaru M, Kawamura T, Ono Y.  Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement . Ann Surg . 1981:194:438-446.Article
9.
Lerut T, Coosemans W, Van Raemdonck D, et al.  Surgical treatment of Barrett's carcinoma: correlations between morphologic findings and prognosis . J Thorac Cardiovasc Surg . 1994;107:1059-1065.
10.
Wang LS, Huang MH, Huang BS, Chien KY.  Gastric substitution for resectable carcinoma of the esophagus: an analysis of 368 cases . Ann Thorac Surg . 1992; 53:289-294.Article
11.
Demeester TR, Attwood SEA, Smyrk TC, Therkildsen DH, Hinder R.  Surgical therapy in Barrett's esophagus . Ann Surg . 1990;212:528-542.Article
12.
Clark GWB, Smyrk TC, Burdiles P, et al.  Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg . 1994;129:609-614.Article
13.
Williamson WA, Ellis FH, Gibb SP, et al.  Barrett's esophagus: prevalence and incidence of adenocarcinoma . Arch Intern Med . 1991;151:2212-2216.Article
14.
McArdle JE, Lewin KJ, Randall G, Weinstein W.  Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus . Hum Pathol . 1992;23:479-482.Article
15.
Kalish RJ, Clancy PE, Orringer MB, Appelman HD.  Clinical, epidemiologic and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia . Gastroenterology . 1984;86:461-467.
16.
Spechler JS, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK.  Prevalence of metaplasia at the gastro-oesophageal junction . Lancet . 1994;344:1533-1536.Article
17.
Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction . Gastroenterology . 1993;104:510-513.
18.
Blot WJ, Devesa SS, Fraumeni JF Jr.  Continuing climb in rates of esophageal adenocarcinoma: an update . JAMA . 1993;270:1320.Article
19.
MacDonald WC, MacDonald JB.  Adenocarcinoma of the esophagus and/or gastric cardia . Cancer . 1987;60:1094-1098.Article
×